scholarly journals The role of IL-17-producing Foxp3+ CD4+ T cells in inflammatory bowel disease and colon cancer

2013 ◽  
Vol 148 (2) ◽  
pp. 246-253 ◽  
Author(s):  
Lequn Li ◽  
Vassiliki A. Boussiotis
2018 ◽  
Vol 214 (8) ◽  
pp. 1095-1104 ◽  
Author(s):  
Xu-Feng Pei ◽  
Long-Lei Cao ◽  
Fang Huang ◽  
Xu Qiao ◽  
Jie Yu ◽  
...  

2019 ◽  
Vol 12 (4) ◽  
pp. 980-989 ◽  
Author(s):  
I. T. Chyuan ◽  
H. F. Tsai ◽  
C. S. Wu ◽  
P. N. Hsu

AbstractTumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces cell apoptosis by transducing apoptosis signals. Recently, accumulating evidence demonstrated that TRAIL regulates autoimmune inflammation and immune cell homeostasis in several autoimmune animal models, suggesting a novel immunoregulatory role of TRAIL in autoimmune diseases. However, the impact of TRAIL in inflammatory bowel disease is yet undefined. This study is to address the therapeutic effects and immunoregulatory role of TRAIL in autoimmune gut inflammation. We demonstrated herein that TRAIL significantly suppressed gut inflammation and reduced the severity of colitis in a dextran sodium sulfate (DSS)-induced colitis model. Suppression of gut inflammation was not due to induction of apoptosis in colonic T cells, dendritic cells, or epithelium cells by TRAIL. In contrast, TRAIL directly inhibited activation of colitogenic T cells and development of gut inflammation in an adoptive transfer-induced colitis model. The anti-inflammatory effects of TRAIL on colitis were abolished when T cells from TRAIL receptor (TRAIL-R) knockout mice were adoptively transferred, suggesting that TRAIL regulates autoreactive colitogenic T-cell activation in the development of gut inflammation. Our results demonstrate that TRAIL effectively inhibited colonic T-cell activation and suppressed autoimmune colitis, suggesting a potential therapeutic application of TRAIL in human inflammatory bowel disease.


2007 ◽  
Vol 13 (7) ◽  
pp. 837-846 ◽  
Author(s):  
Taku Kobayashi ◽  
Susumu Okamoto ◽  
Yuko Iwakami ◽  
Atsushi Nakazawa ◽  
Tadakazu Hisamatsu ◽  
...  

2019 ◽  
Vol 12 (5) ◽  
pp. 1201-1211 ◽  
Author(s):  
S. Veenbergen ◽  
P. Li ◽  
H. C. Raatgeep ◽  
D. J. Lindenbergh-Kortleve ◽  
Y. Simons-Oosterhuis ◽  
...  

2010 ◽  
Vol 51 (5) ◽  
pp. 563-572 ◽  
Author(s):  
Raffaella La Scaleia ◽  
Stefania Morrone ◽  
Antonella Stoppacciaro ◽  
Stefania Scarpino ◽  
Manila Antonelli ◽  
...  

2021 ◽  
Vol 12 ◽  
Author(s):  
Rosaely Casalegno Garduño ◽  
Jan Däbritz

CD8+ T cells are involved in the pathogenesis of inflammatory bowel disease (IBD), a complex multifactorial chronic disease. Here, we present an overview of the current research with the controversial findings of CD8+ T cell subsets and discuss some possible perspectives on their therapeutic value in IBD. Studies on the role of CD8+ T cells in IBD have contradictory outcomes, which might be related to the heterogeneity of the cells. Recent data suggest that cytotoxic CD8+ T cells (Tc1) and interleukin (IL) 17-producing CD8+ (Tc17) cells contribute to the pathogenesis of IBD. Moreover, subsets of regulatory CD8+ T cells are abundant at sites of inflammation and can exhibit pro-inflammatory features. Some subsets of tissue resident memory CD8+ T cells (Trm) might be immunosuppressant, whereas others might be pro-inflammatory. Lastly, exhausted T cells might indicate a positive outcome for patients. The function and plasticity of different subsets of CD8+ T cells in health and IBD remain to be further investigated in a challenging field due to the limited availability of mucosal samples and adequate controls.


2020 ◽  
Vol 118 (3) ◽  
pp. 420a
Author(s):  
Susumu Ohya ◽  
Kyoko Endo ◽  
Hiroaki Kito ◽  
Junko Kajikuri ◽  
Takayoshi Suzuki

Blood ◽  
2006 ◽  
Vol 108 (7) ◽  
pp. 2300-2306 ◽  
Author(s):  
Régis Peffault de Latour ◽  
Hélène C. Dujardin ◽  
Florence Mishellany ◽  
Odile Burlen-Defranoux ◽  
Julien Zuber ◽  
...  

Abstract Mice lacking interleukin-7 (IL-7–/– mice) have no signs of autoimmune disease, contrary to other models of lymphopenia. We investigated whether the absence of disease was due to the fact that IL-7 is dispensable for the ontogeny, function, and homeostasis of regulatory CD4+ T cells. We show here that the establishment of the peripheral pool of Foxp3-expressing regulatory cells is IL-7 independent, and the premature involution of the thymus in IL-7–/– mice does not change the representation of the CD4+CD25+ T-cell compartment. In addition, CD4+CD25+ T cells expand in the absence of IL-7, without losing Foxp3 expression. The frequency of activated peripheral CD4+ T cells increases with age in both the CD25– and CD25+ compartments, with the CD4+CD25+ T cells displaying signs of constant activation. IL-7–/– CD4+CD25+ T cells control inflammatory bowel disease induced by IL-7–/– T cells even in hosts lacking IL-7. Depletion of the CD25+ T-cell subset after thymic involution results in a mild form of inflammatory bowel disease (IBD), which resolves concomitantly with the regeneration of this subset. This study shows for the first time that IL-7–/– mice have a robust regulatory Foxp3-expressing CD4+ T-cell compartment that controls T-cell–mediated disease. It also highlights the potential of the regulatory Foxp3-expressing CD4+CD25– T-cell population to restore a functional CD4+CD25+ T-cell compartment through an IL-7–independent pathway.


1991 ◽  
Vol 101 (6) ◽  
pp. 1594-1605 ◽  
Author(s):  
Kazuo Kusugami ◽  
Toshihiro Matsuura ◽  
Gail A. West ◽  
Kenneth R. Youngman ◽  
Daniel Rachmilewitz ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document